enGene Announces Poster Presentation at the Society of Urologic Oncology 2021 Annual Meeting
- Preclinical EG-70 studies reveal durable systemic anti-tumor immunity and robust efficacy in an orthotopic murine model of bladder cancer
- EG-70 is a first-in-class non-viral genetic medicine encoding RIG-I activators and IL-12 as an intravesical monotherapy
BOSTON, Mass. and MONTRÉAL, Dec. 1, 2021 /CNW/ - enGene Inc., a clinical-stage biotechnology company developing non-viral gene therapies for local administration into mucosal tissues enabled by its proprietary DDX platform, today announced a poster presentation at the upcoming Society of Urologic Oncology Annual Meeting being held from December 1 to December 3, 2021. The poster will highlight the robust preclinical efficacy and mechanism of action studies of EG-70, the company's lead asset for non-muscle invasive bladder cancer (NMIBC), in an orthotopic murine model of bladder cancer.
Title: EG-70 is a first-in-class intravesical non-viral gene therapy for local expression of innate and adaptive immune modulators for treatment of non-muscle invasive bladder cancer
Category: Bladder Cancer - Non-Muscle Invasive Bladder Cancer
Abstract Number: 230
Date and Time: Friday December 3rd; e-Poster
Based on enGene's proprietary DDX platform, EG-70 is a non-viral gene therapy encoding two RIG-I agonists to stimulate the innate immune system, and IL-12 to stimulate the adaptive immune system. By stimulating both arms of the immune system, intravesically administered EG-70 yields remarkable tumor regression in preclinical models of bladder cancer with induction of effective immunological memory and minimal signs of toxicity. A first-in-human Phase 1/2 clinical trial (the LEGEND study) is ongoing to evaluate safety and efficacy of EG-70 in patients with BCG-unresponsive NMIBC (clinicaltrials.gov).
Additional meeting information and the published abstract are available on the SUO website.
About enGene Inc.
enGene Inc. is a clinical-stage biotechnology company developing non-viral gene therapies based on localized delivery of nucleic acid payloads to mucosal tissues. The dually derived chitosan (DDX) platform has a high-degree of payload flexibility including DNA and various forms of RNA with broad tissue and disease applications. In preclinical models, enGene's DDX technology has been demonstrated to effectively induce expression of therapeutic genes following delivery to the lung, gastrointestinal tract and urinary bladder. enGene has developed scalable GMP-compliant manufacturing of DDX products. http://www.engene.com
Note regarding forward-looking statements
This press release contains certain "forward-looking statements" that reflect the Company's beliefs This press release contains certain "forward-looking statements" that reflect the Company's beliefs and assumptions based on currently available data and information. These forward-looking statements fall within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "target," "believe," "expect," "will," "may," "anticipate," "estimate," "would," "positioned," "future," and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on enGene's current beliefs, expectations, and assumptions that by definition involve risks, uncertainties, that are difficult to predict and are subject to factors outside of management's control and that could cause actual results to differ substantially from statements made including but not limited to: risks associated with the success of preclinical studies, clinical trials, research and development programs, as well as regulatory approval processes. Actual results and outcomes may differ materially from those indicated in the forward-looking statements. enGene has no approved drugs available for sale marketing at this time and may never have an approved drug. You are cautioned not to rely on enGene's forward looking statements, which are only made as of the date hereof. The Company is under no obligation to update these statements.
SOURCE enGene
Jason Hanson, President and CEO, enGene Inc., [email protected], Tel: 514-332-4888 Ext. 100
Share this article